Literature DB >> 29880656

QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study.

Lorenzo Guglielmetti1,2,3, Simon Tiberi4,5, Matthew Burman5, Heinke Kunst5, Christian Wejse6, Tamar Togonidze7, Graham Bothamley8, Christoph Lange9,10,11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29880656     DOI： 10.1183/13993003.00537-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  10 in total

1.  Safety of prolonged treatment with bedaquiline in programmatic conditions.

Authors:  Dzmitriy Zhurkin; Elmira Gurbanova; Jonathon R Campbell; Dick Menzies; Svetlana Setkina; Hennadz Hurevich; Varvara Solodovnikova; Dzmitry Viatushka; Alan Altraja; Alena Skrahina
Journal:  ERJ Open Res       Date:  2022-05-16

2.  Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples.

Authors:  Andrew Reckers; Stella Huo; Ali Esmail; Keertan Dheda; Peter Bacchetti; Monica Gandhi; John Metcalfe; Roy Gerona
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2020-12-10       Impact factor: 3.205

3.  QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.

Authors:  Kelly E Dooley; Susan L Rosenkranz; Francesca Conradie; Laura Moran; Richard Hafner; Florian von Groote-Bidlingmaier; Javier R Lama; Justin Shenje; Jorge De Los Rios; Kyla Comins; Joel Morganroth; Andreas H Diacon; Yoninah S Cramer; Kathleen Donahue; Gary Maartens
Journal:  Lancet Infect Dis       Date:  2021-02-12       Impact factor: 71.421

4.  Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects.

Authors:  Soyoung Shin; Beom Soo Shin; Jeongjun Kim; Jinho Choi; Hwankyu Kang; Jiye Ahn; Jane Hutchings; Christo van Niekerk; Dongsik Park; Jaeseung Kim; Yeejin Jeon; Kiyean Nam
Journal:  Antimicrob Agents Chemother       Date:  2021-10-25       Impact factor: 5.938

5.  Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.

Authors:  Lawrence Mbuagbaw; Lorenzo Guglielmetti; Catherine Hewison; Nyasha Bakare; Mathieu Bastard; Eric Caumes; Mathilde Fréchet-Jachym; Jérôme Robert; Nicolas Veziris; Naira Khachatryan; Tinatin Kotrikadze; Armen Hayrapetyan; Zaza Avaliani; Holger J Schünemann; Christian Lienhardt
Journal:  Emerg Infect Dis       Date:  2019-05       Impact factor: 6.883

6.  Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California.

Authors:  Shereen Katrak; Phil Lowenthal; Richard Shen; Lisa True; Leslie Henry; Pennan Barry
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-01-10

7.  Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data.

Authors:  Levin Thomas; Sumit Raosaheb Birangal; Rajdeep Ray; Sonal Sekhar Miraj; Murali Munisamy; Muralidhar Varma; Chidananda Sanju S V; Mithu Banerjee; Gautham G Shenoy; Mahadev Rao
Journal:  Ther Adv Drug Saf       Date:  2021-08-26

Review 8.  Computational methods directed towards drug repurposing for COVID-19: advantages and limitations.

Authors:  Prem Prakash Sharma; Meenakshi Bansal; Aaftaab Sethi; Lindomar Pena; Vijay Kumar Goel; Maria Grishina; Shubhra Chaturvedi; Dhruv Kumar; Brijesh Rathi
Journal:  RSC Adv       Date:  2021-11-10       Impact factor: 4.036

9.  Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.

Authors:  Shao-Jun Zhang; Yan Yang; Wen-Wen Sun; Zhong-Shun Zhang; He-Ping Xiao; Yu-Ping Li; Zhe-Min Zhang; Lin Fan
Journal:  BMC Infect Dis       Date:  2022-08-29       Impact factor: 3.667

10.  Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.

Authors:  Catherine Hewison; Uzma Khan; Mathieu Bastard; Nathalie Lachenal; Sylvine Coutisson; Elna Osso; Saman Ahmed; Palwasha Khan; Molly F Franke; Michael L Rich; Francis Varaine; Nara Melikyan; Kwonjune J Seung; Malik Adenov; Sana Adnan; Narine Danielyan; Shirajul Islam; Aleeza Janmohamed; Hayk Karakozian; Maureen Kamene Kimenye; Ohanna Kirakosyan; Begimkul Kholikulov; Aga Krisnanda; Andargachew Kumsa; Garmaly Leblanc; Leonid Lecca; Mpiti Nkuebe; Shahid Mamsa; Shrivani Padayachee; Phone Thit; Carole D Mitnick; Helena Huerga
Journal:  Clin Infect Dis       Date:  2022-09-29       Impact factor: 20.999
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.